Compound: Finerenone
SMILES: O=C(N)C1=C(Nc2c(cnc(c2[C@@H]1c3c(OC)cc(C#N)cc3)OCC)C)C
InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N
Synonyms: Finerenone, 1050477-31-0, Kerendia, BAY94-8862, (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, BAY 94-8862, finerenona, DE2O63YV8R, BAY-94-8862, (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide, DTXSID10146928, finerenonum, RefChem:57201, DTXCID5069419, 814-499-5, Finerenone (BAY 94-8862), (S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-, Finerenone [USAN:INN], UNII-DE2O63YV8R, Finerenone?, Kerendia (TN), Finerenone; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide; BAY 94-8862; Finerenone, Finerenone (Standard), FINERENONE [INN], FINERENONE [JAN], FINERENONE [USAN], FINERENONE [WHO-DD], Finerenone (JAN/USAN/INN), GTPL8678, orb1306378, SCHEMBL8157011, FINERENONE [ORANGE BOOK], SCHEMBL29623206, SCHEMBL30978927, WLZ3553, GLXC-15655, 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-, EX-A2845, MFCD29047135, HY-111372R, AC-30916, DA-53198, MS-26172, HY-111372, CS-0040097, D10633, F53302, Q21099046, (4S)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Theoretical properties:
molecular_formula: C21H22N4O3
molecular_weight: 378.4 g/mol
exact_mass: 378.16919058 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 5
heavy_atom_count: 28
topological_polar_surface_area: 110 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
chebi: A non-steroidal mineralocorticoid receptor antagonist used to reduce the risk of more heart or kidney damage in patients with chronic kidney disease and type 2 diabetes.
chembl: FINERENONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It is taken orally (swallowed by mouth).
Common side effects include abnormally high levels of potassium in the bloodstream, abnormally low levels of sodium in the bloodstream, and abnormally low blood pressure.
Finerenone was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The US Food and Drug Administration considers it to be a first-in-class medication.